Simulations Plus (SLP) to Release Quarterly Earnings on Tuesday

Simulations Plus (NASDAQ:SLP) will announce its earnings results after the market closes on Tuesday, July 2nd. Analysts expect the company to announce earnings of $0.17 per share for the quarter. Simulations Plus has set its FY24 guidance at $0.66-0.68 EPS and its FY 2024 guidance at 0.660-0.680 EPS.Investors that are interested in registering for the company’s conference call can do so using this link.

Simulations Plus (NASDAQ:SLP) last released its quarterly earnings data on Wednesday, April 3rd. The technology company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $0.02. The firm had revenue of $18.31 million during the quarter, compared to the consensus estimate of $17.31 million. Simulations Plus had a net margin of 16.22% and a return on equity of 7.95%. The firm’s revenue was up 16.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.20 earnings per share. On average, analysts expect Simulations Plus to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Simulations Plus Price Performance

Simulations Plus stock opened at $48.62 on Monday. The company has a market cap of $971.91 million, a PE ratio of 91.74 and a beta of 0.75. The company has a fifty day moving average price of $47.77 and a two-hundred day moving average price of $44.12. Simulations Plus has a 12 month low of $32.69 and a 12 month high of $52.69.

Simulations Plus Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, May 6th. Shareholders of record on Monday, April 29th were issued a $0.06 dividend. This represents a $0.24 dividend on an annualized basis and a yield of 0.49%. The ex-dividend date was Friday, April 26th. Simulations Plus’s dividend payout ratio is presently 45.28%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on SLP shares. Craig Hallum raised their target price on Simulations Plus from $51.00 to $56.00 and gave the company a “buy” rating in a research note on Thursday, June 13th. Oppenheimer raised their target price on Simulations Plus from $55.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday, June 13th. Finally, William Blair started coverage on Simulations Plus in a research note on Friday. They issued an “outperform” rating on the stock.

Insider Activity at Simulations Plus

In related news, Director Daniel L. Weiner sold 3,250 shares of Simulations Plus stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $48.31, for a total transaction of $157,007.50. Following the sale, the director now directly owns 8,759 shares in the company, valued at $423,147.29. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $45.95, for a total transaction of $919,000.00. Following the transaction, the director now directly owns 3,580,857 shares of the company’s stock, valued at $164,540,379.15. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Daniel L. Weiner sold 3,250 shares of Simulations Plus stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $48.31, for a total value of $157,007.50. Following the transaction, the director now directly owns 8,759 shares in the company, valued at $423,147.29. The disclosure for this sale can be found here. Insiders have sold a total of 23,750 shares of company stock worth $1,101,008 over the last ninety days. 20.90% of the stock is currently owned by corporate insiders.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.